mCRPC: Assessing Progression from Asymptomatic to Symptomatic Disease

mCRPC: Progression from Asymptomatic to Symptomatic Disease and Approaches to Patient Treatment

A review of radium-223 in the newly symptomatic mCRPC patient. The mechanism of action and radium-223 pivotal trial results are discussed. The assessment of treatment response with radium-223 is illustrated in this patient case study.

Alicia K. Morgans, MD
Vanderbilt Ingram Cancer Center - University Medical Center, Divison of Hematology/Oncology 

Dr. Morgans specializes in the treatments of genitourinary malignancies, including cancers of the prostate, bladder, testis (germ cell) and penis.

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe